

# Matthew Becker Speaks With PharmaWire on the Potential Patent Life of BTC and Johnson & Johnson's Abiraterone Drug For Prostate Cancer

NEWS | 1 MIN READ

November 29, 2010

PharmaWire reported on November 29, 2010 that the patent life of BTG and Johnson & Johnson's potential prostate cancer blockbuster abiraterone is unclear due to laws changed in 1995 for calculating expiration dates. According to BTG, abiraterone is protected until 2024. Although abiraterone is a simple molecule that will be reproduced by generic companies very easily and the drug may have a short patent life relying on data exclusivity, experts believe the data is still striking enough to secure a large market share in this timeframe. The companies are expected to also file for an extension of the patent for up to five years. However, patents covering manufacturing and synthesis methods typically cannot be enforced against generic applicants until shortly prior to commercial launch, Matthew Becker, a patent attorney at Axinn, noted in the article.

## Related People

---



Matthew J. Becker

# Related Services

---

Intellectual Property

To subscribe to our publications, [click here](#).

## Featured Insights

- GCR Live: Law Leaders Europe 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- AHLA Annual Meeting 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- SABA North America Annual Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses  
**WEBINAR    ANTITRUST**
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025  
**SPONSORSHIP    ANTITRUST**
- NJSBA Annual Meeting and Convention 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You  
**WEBINAR    INTELLECTUAL PROPERTY**
- Hartford HealthCare Black and Red Gala 2025  
**SPONSORSHIP    ANTITRUST**
- Informa CompLaw Antitrust West Coast Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**

- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
- AXINN VIEWPOINTS      LITIGATION & TRIALS**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved